Tadalafil-associated anterior ischaemic optic neuropathy [19]

Eye

Volumn 19, Issue 6, 2005, Pages 715-717

  Peter, Neena M ^a,b   Singh, M V ^a   Fox, P D ^a  

^a WORTHING HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TADALAFIL;

ADULT; BLOOD PRESSURE MEASUREMENT; CASE REPORT; COLOR VISION; DISEASE ASSOCIATION; ERECTILE DYSFUNCTION; FLUORESCENCE ANGIOGRAPHY; HEADACHE; HUMAN; ISCHEMIC OPTIC NEUROPATHY; LETTER; MALE; OPHTHALMOSCOPY; PERIMETRY; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; VISUAL ACUITY; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; VISUAL SYSTEM EXAMINATION;

EID: 21244463854     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.eye.6701614     Document Type: Letter

References (9)

1. Pomeranz HD, Smith KH, Hart Jr WM, Egan RA. Sildenafil-associated nonarteritic anterior ischaemic optic neuropathy. Ophthalmology 2002; 109(3): 584-587.
2. Dheer S, Rekhi GS, Merlyn S. Sildenafil associated anterior ischaemic optic neuropathy. J Assoc Physicians India 2002; 50: 265.
3. Boshier A, Pambakian N, Shakir SAW. A case of NAION in a male patient taking sildenafil. Int J Clin Pharmacol Ther 2000; 40(9): 422-423.
4. Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil - review of the literature. Eur J Med Res 2002; 7(10): 435-446.
5. Study 148-223: A double-blind, randomised, placebo controlled, four period crossover study to assess the effect of orally administered sildenafil (50, 100 and 200 mg) on visual function on healthy male volunteers. Viagra: Joint Clinical Review for NDA-20-895 Centre for Drug Evaluation and Research, FDA, Washington, DC, 1998, pp 160-161.
6. Padma-Nathan H. Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction. Am J Cardiol 2003; 92(9A): 19M-25M.
7. Ischaemic Optic Neuropathy Decompression Trial Study Group 666). Characteristics of patients with NAION eligible for the Ischaemic Optic Neuropathy Decompression Trial. Arch Ophthalmol 1996; 114: 1366-1374.
8. Burdle RM. Optic disc risk factors for NAI0N. Am J Ophthalmol 1993; 116: 759-764.
9. US Food and Drug Administration - Cialis. Department of Health and Human Services. Updated November 2003.